Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
ListedSMEHospital & Healthcare ServicesQLINE

Q-Line Biotech IPO

Q-Line Biotech IPO is an SME IPO raising ₹214 Cr at ₹326 – ₹343 a share. It listed on 29 May 2026 at ₹452, +31.8% against its issue price of ₹343, and trades at ₹715 today (+108.4% since issue). It was subscribed 119× in total.

Get alerts on this companyCompany page
₹343
Issue price
₹715
Price now
+108.4%
Since issue price
29 May 2026
Listed on
119×Subscribed (final) · all exchanges

119.3 times more demand than shares on offer

populated partly populated we hold nothing here — the tab says why

How its cohort has done

131 SME issues listed in 2026 that we can price today. This is the group this issue belongs to.

+8.4%
Median return since issue price
46.6%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidNot available from NSE for this issue
How demand built over timeFinal figure held, but no series — we were not sampling this issue while it was live
Price-point demand curveLive only — NSE stops serving this once bidding closes
Lead managers and registrar2 banks
Official documents3 documents
Listing-day priceOpened at ₹452 on debut
Performance since listingComputed from our own daily closes

Led by Hem Securities Limited — median +40.2% across the 47 of its issues we can price. All lead managers →

What happens when

20 MayPre-apply
21 MayBidding opens
25 MayBidding closes
27 MayAllotment
27 MayRefunds
29 MayListing
6 JulMandate ends

Track Q-LINE BIOTECH LIMITED

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.